Related Experiment Video
Updated: Mar 15, 2026

07:41
Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
2.5K
Percutaneous Double Lumen Cannula for Right Ventricle Assist Device System: A Computational Fluid Dynamics Study
Francesca Condemi1, Dongfang Wang1, Gionata Fragomeni2
1Department of Surgery, Cardiothoracic Surgery Division, University of Kentucky.
Biocybernetics and Biomedical Engineering
|August 30, 2016
Summary
This study developed a double lumen cannula (DLC) for percutaneous right ventricular assist devices (pRVAD), showing it handles high flow with minimal hemolysis. Further design improvements are needed to prevent blood stagnation and thrombosis risks.
Area of Science:
- Biomedical Engineering
- Cardiovascular Devices
- Fluid Dynamics
Background:
- Percutaneous right ventricular assist devices (pRVAD) require surgical implantation and removal.
- A double lumen cannula (DLC) offers a less invasive alternative for pRVAD installation and explantation.
- Minimally invasive cardiac support devices are crucial for improving patient outcomes.
Purpose of the Study:
- To develop and evaluate a novel double lumen cannula (DLC) for a percutaneous right ventricular assist device (pRVAD).
- To assess the performance, flow patterns, blood hemolysis, and thrombosis potential of the pRVAD DLC.
- To determine the feasibility of reducing open-chest surgeries for RVAD procedures.
Main Methods:
- Computational fluid dynamics (CFD) simulations using finite volume and shear-stress transport k-ω models.
- Laminar flow model for Reynolds numbers <4000 and turbulent model for Reynolds numbers >4000.
- Bench testing of a 27 Fr prototype to validate CFD results.
Main Results:
- CFD pressure drop results showed less than 1.3% difference compared to experimental data.
- Lagrangian analysis indicated low hemolysis rates (0.012% drainage, 0.0073% infusion) at 5 L/min.
- CFD identified blood stagnancy and recirculation zones, suggesting potential thrombosis risk.
Conclusions:
- The pRVAD DLC demonstrates capability for high flow rates (up to 5 L/min) with acceptable hemolysis.
- Design modifications are necessary to mitigate identified blood stagnancy and recirculation.
- Further development is required to optimize the pRVAD DLC for safe and effective clinical use.

